EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Role of clinical biomarkers in predicting the effectiveness of omalizumab

Qing Zhang iD, Chunxiao Li, Jingxuan Wan, Mengyuan Zhang, Ying Nong, Jiangtao Lin iD

Therapeutic Advances in Respiratory Disease · 2023

DOI: 10.1177/17534666231170821 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2023. Verfasst von Qing Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To explore whether baseline clinical biomarkers and characteristics can be used to predict the responsiveness of omalizumab.

Methods

We retrospectively analyzed a cohort of patients with severe asthma who received omalizumab treatment and collected their baseline data and relevant laboratory examination results along with case records of omalizumab treatment responsiveness after 16 weeks. We compared the differences in variables between the group of patients that responded to omalizumab therapy and the non-responder group, and then performed univariate and multivariate logistic regression. Finally, we analyzed the difference in response rate for subgroups by selecting cut-off values for the variables using Fisher’s exact probability method.

Results

This retrospective, single-center observational study enrolled 32 patients with severe asthma who were prescribed daily high-dose inhaled corticosteroids and long-acting β2 receptor agonists on long-acting muscarinic receptor antagonists with or without OCS. Data on age, sex, BMI, bronchial thermoplasty, FeNO, serum total IgE, FEV1, blood eosinophils, induced sputum eosinophils, blood basophils, and complications were not significantly different between the responder and non-responder groups. In the univariate and multivariate logistic regression, all the variants were not significant, and we were unable to build a regression model. We used normal high values and the mean or median of variables as cut-off values to create patient subgroups for the variables and found no significant difference in the omalizumab response rate between the subgroups.

Conclusion

The responsiveness of omalizumab is not associated with pretreatment clinical biomarkers, and these biomarkers should not be used to predict the responsiveness of omalizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Asthmatic AgentsAsthmaHumansOmalizumabRetrospective StudiesTreatment OutcomeBiomarkers

Stichwörter der Autor:innen

baseline clinical characteristicsbiomarkeromalizumabresponsesevere asthma

Substanzen

OmalizumabAnti-Asthmatic AgentsBiomarkers

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Department of Pulmonary and Critical Care Medicine, National Regional Center for Respiratory Medicine, Jiangxi hospital of China-Japan Friendship Hospital, Nanchang, China.
  • Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
  • Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China.
  • Department of Pulmonary and Critical Care Medicine, National Clinical Research Center for Respiratory Disease, China-Japan Friendship Hospital, Beijing, China.
  • Department of Pulmonary and Critical Care Medicine, National Clinical Research Center for Respiratory Medicine, China-Japan Friendship Hospital, No. 2, East Yinghua Road, Chaoyang, Beijing 100029, China.

ORCID-Profile: Qing Zhang, Jiangtao Lin

Zitieren

APA

Zhang, Q., Li, C., Wan, J., Zhang, M., Nong, Y., & Lin, J. (2023). Role of clinical biomarkers in predicting the effectiveness of omalizumab. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666231170821

Vancouver

Zhang Q, Li C, Wan J, Zhang M, Nong Y, Lin J. Role of clinical biomarkers in predicting the effectiveness of omalizumab. Therapeutic Advances in Respiratory Disease. 2023. doi:10.1177/17534666231170821

BibTeX
@article{Zhang2023,
  author = {Zhang, Qing and Li, Chunxiao and Wan, Jingxuan and Zhang, Mengyuan and Nong, Ying and Lin, Jiangtao},
  title = {Role of clinical biomarkers in predicting the effectiveness of omalizumab},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2023},
  doi = {10.1177/17534666231170821}
}
Kostenlos starten →